Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of NanoMab Technology.

    Client Virtual Booth

    NANOMAB TECHNOLOGY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    NanoMab Technology
    China Flag
    Country
    Country
    China
    Address
    Address
    Rm 3-150, 3/F, China Merchants Plaza, 333 North Chengdu Road, Jingan District, Shanghai 200041
    Telephone
    Telephone
    +86 021 6229 9192
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://nano-mab.com/global/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/nanomab/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    NanoMab and OncoBeta Outline the Pathway to a Strategic Alliance and Supply Agreement Focused on the Secure Supply of Rhenium-188

    Details:

    The Heads of Terms will initiate a Strategic Partnership and Supply Agreement for the development of Rhenium-188 API solutions that are appropriate for labelling the NanoMab range of nanobodies for the production of therapeutic radiopharmaceuticals.


    Lead Product(s): Rhenium-188

    Therapeutic Area: Oncology Product Name: Rhenium-188

    Highest Development Status: UndisclosedProduct Type: Small molecule

    Recipient: OncoBeta

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement October 27, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    NanoMab and University Hospital Aachen to Start a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product

    Details:

    The programme will utilise Nanomab’s next generation NM-02 radiopharmaceutical product targeting a First in Human (FIH) administration to develop novel radiopharmaceutical product for patients with HER2 positive breast cancer.


    Lead Product(s): NM-02

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: University Hospital Aachen

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement May 21, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search